Skin Cancer, Acne, Skin Injury | Dermatology News, Treatment …
WEBBy Alan P. Lyss, MD. Factors preventing more widespread use of biosimilars in oncology include the cost and complexity of biosimilar development, oncologists’ lack of knowledge about biosimilars, and the fact that interactions between payers, manufacturers, and pharmacy benefit managers can sometimes drive up the cost of biosimilars.
AAD Issues New Guidelines for Clinical Management of Acne …
WEBMar 22, 2024 · The American Academy of Dermatology (AAD) has issued updated guidelines for the clinical management of patients with acne vulgaris, which have been published in the Journal of the American Academy of Dermatology.. Systematic reviews to evaluate the effectiveness and safety of acne treatments approved by the United States Food and Drug Administration (FDA) were performed from May 2021 to ...
Treatment of Moderate to Severe Atopic Dermatitis: Highlights …
WEBFrom March 17 to 21, 2023, dermatologists gathered for the American Academy of Dermatology (AAD) Annual Meeting, where they discussed the latest research on the treatment and management of a range of inflammatory skin diseases and other conditions. In this article, Emma Guttman-Yassky, MD, PhD, discusses the most exciting research on the treatment of moderate to severe atopic dermatitis ...
An Updated Review of Melasma Treatments - Dermatology Advisor
WEBAugust 26, 2022. A review from an international team of researchers summarizes the available medical therapies for melasma and offers suggestions and recommendations for the use of these therapies in clinical practice. The review was published online in the Journal of Cosmetic Dermatology. 1. Medical Therapies for Melasma.
Exploring the Efficacy of Targeted Systemic Therapies for …
WEBOctober 24, 2023. Upadacitinib 30 mg was found to be the most efficacious targeted therapy across all endpoints for the treatment of moderate to severe atopic dermatitis, followed by abrocitinib 200 mg, and upadacitinib 15 mg. After 12 to 16 weeks of treatment with upadacitinib 30 mg, adults with moderate to severe atopic dermatitis (AD) saw ...
JADE Trials: Long-Term Abrocitinib Use Safe for Patients With …
WEBJuly 30, 2024. Findings from the JADE trials show that abrocitinib at 100 mg and 200 mg was well-tolerated among patients with moderate to severe atopic dermatitis. Abrocitinib has a manageable long-term safety profile among patients with moderate to severe atopic dermatitis (AD) who require systemic therapy, according to study results ...
Zoryve Cream 0.15% Approved for Atopic Dermatitis
WEBJul 12, 2024 · The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. The approval was supported by data from the phase 3 INTEGUMENT-1 (ClinicalTrials.gov Identifier: NCT04773587 ...
Efficacy of Upadacitinib vs Dupilumab for Atopic Dermatitis
WEBSep 20, 2021 · At week 16, 71.0% of the upadacitinib arm and 61.1% of the dupilumab arm achieved EASI75 (P =.006). All secondary endpoints supported the superior efficacy of upadacitinib. A significantly greater percentage of patients in the upadacitinib group achieved EASI100 at week 16 compared to the dupilumab group (27.9% vs 7.6%; P <.001).
NICE Guideline Provides Updated Recommendations for Acne …
WEBThe NICE guideline suggests clinicians may wish to consider continuing oral and topical treatments for up to 12 additional weeks if acne is improving but not yet clear. In mild to moderate acne, the NICE guideline recommends offering patients another first-line treatment option. In moderate to severe cases that failed to respond to a 12-week ...
Emerging Therapies Show Promise for Atopic Dermatitis
WEBMar 3, 2021 · Advances in the understanding of the pathophysiology of atopic dermatitis (AD) have led to an increase in immunomodulating treatments under investigation, according to commentary published in the British Journal of Dermatology. 1. The ECZTRA 1, 2, and 3 trials have recently found that tralokinumab, a biologic inhibitor of interleukin (IL)-13, is beneficial for patients with moderate to severe AD.
Skip to content